Stockscreener 앱 받기
159.00
1.65%
2.58
시간 외 거래:
159.00
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill
Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia
Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com Australia
Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - PR Newswire
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now? - Insider Monkey
Neurocrine presents 2-year Crenessity data at ENDO 2026 By Investing.com - Investing.com South Africa
Neurocrine (NBIX) Reports Positive Phase 3 Data on Crenessity - GuruFocus
Neurocrine reports positive 2-year pediatric CAH data - grafa.com
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH - The Pharma Letter
Neurocrine presents 2-year Crenessity data at ENDO 2026 - Investing.com UK
Neurocrine Biosciences Presents New Two-Year CRENESSITY Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults With Classic Congenital Adrenal Hyperplasia - marketscreener.com
Neurocrine presents two-year pediatric data for Crenessity - Investing.com
Neurocrine presents two-year CRENESSITY data showing growth improvements - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - PR Newswire
Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Investor Outlook Highlights 20.73% Potential Upside - DirectorsTalk Interviews
How New INGREZZA TD Data in Underserved Patients Could Shape Neurocrine Biosciences’ (NBIX) Investment Story - simplywall.st
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - simplywall.st
Neurocrine Biosciences (NBIX) beats Q1 earnings and revenue estimates - MSN
INGREZZA Data In Complex Patients Adds Support For Neurocrine Valuation Story - simplywall.st
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys - Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy - ChartMill
Neurocrine Biosciences(NBIX.US) Director Sells US$4.13 Million in Common Stock - Moomoo
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock - Investing.com UK
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock By Investing.com - Investing.com Canada
Neurocrine (NBIX) director exercises 25K options and sells 25K shares under 10b5-1 plan - Stock Titan
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com
Neurocrine Biosciences (NBIX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com
Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider
Neurocrine Biosciences director sells $210,071 in stock By Investing.com - Investing.com South Africa
Neurocrine Biosciences director sells $210,071 in stock - Investing.com
Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan
Drug for uncontrollable movements eased symptoms in 94% of patients over 48 weeks - Stock Titan
Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com
Neurocrine presents data on tardive dyskinesia treatment - Investing.com
Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia
Doctors report TD reductions, better speech and socializing with INGREZZA - Stock Titan
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine Biosciences Inc. (NBIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Does Neurocrine Biosciences’ (NBIX) Rare Disease Push Quietly Rewire Its Endocrine Risk-Reward Profile? - simplywall.st
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $5,770,235, According to a Recent SEC Filing - Moomoo
Neurocrine Biosciences(NBIX.US) Officer Sells US$5.77 Million in Common Stock - Moomoo
Baird reiterates Neurocrine Bio stock rating on acquisition potential - Investing.com
1.93%
0.58%
자본화:
|
볼륨(24시간):